At-Home EEG Headset Tracks Alzheimer's Biomarkers Over a Full Year
A 52-week study shows patients with mild Alzheimer's can reliably complete unsupervised brain scans and cognitive tests at home.
Summary
Cumulus Neuroscience has validated a home-based brain monitoring platform for Alzheimer's disease research. The NeuLogiQ system pairs a wireless EEG headset with tablet-based cognitive games and cloud tracking. In a 119-person UK trial spanning 52 weeks, participants with mild Alzheimer's dementia and healthy controls completed nearly all initiated sessions, with adherence rates of 77% and 89% respectively. The platform captured brain activity, cognition, mood, speech, and sleep without clinic visits. Results published in Frontiers in Digital Health suggest that frequent, low-burden digital biomarkers could replace or supplement traditional pen-and-paper assessments in Alzheimer's trials, potentially speeding up drug development and enabling earlier detection of cognitive decline.
Detailed Summary
Monitoring brain health continuously — rather than in brief annual clinic snapshots — has long been a goal for Alzheimer's researchers and health-conscious adults alike. A new study from Cumulus Neuroscience brings that goal closer to reality by demonstrating that people can reliably use a sophisticated brain-monitoring system entirely at home, unsupervised, for a full year.
The CNS-101 study enrolled 119 participants across seven UK clinical sites: 59 with mild Alzheimer's disease dementia and 60 age-matched healthy controls. Participants used the NeuLogiQ platform, which combines a self-setup wireless dry-sensor EEG headset — cleared as a Class 1 medical device by both the FDA and UK regulators — with gamified neurocognitive tablet tests and cloud-based data infrastructure. The protocol measured brain electrical activity, cognition, mood, speech, and sleep quality over 52 weeks.
Adherence was notably strong. Participants completed 99.7% of sessions they initiated. Overall adherence averaged 77% in the Alzheimer's group and 88.8% among healthy controls — figures that compare favorably with many clinic-based trial protocols. Usability ratings remained positive throughout the year-long study. The platform was developed in collaboration with ten pharmaceutical companies, signaling strong industry interest in its application to drug trials.
The practical implications extend beyond clinical trials. Technologies like this could one day allow individuals to track their own cognitive trajectories at home, catching subtle declines years before symptoms become disabling. For longevity-focused adults, frequent objective brain health monitoring represents a meaningful addition to the biomarker toolkit alongside blood panels and fitness metrics.
Important caveats apply. This was a feasibility study, not a treatment trial, so no conclusions about drug efficacy or individual risk reduction can be drawn. Longer-term validation in larger, more diverse populations is still needed before at-home EEG becomes standard clinical practice.
Key Findings
- 119 participants completed a 52-week home EEG and cognitive testing protocol with 99.7% session completion rate.
- Alzheimer's patients achieved 77% adherence; healthy controls reached 88.8% over the full year.
- The wireless dry-sensor EEG headset is FDA 510(k)-cleared and UKCA-marked as a Class 1 medical device.
- Platform captured cognition, mood, speech, and sleep — replacing burdensome clinic visits with home monitoring.
- Developed with ten pharma companies, the system targets use as a digital biomarker tool in Alzheimer's drug trials.
Methodology
This is a news report summarizing a peer-reviewed feasibility study published in Frontiers in Digital Health. The source, Longevity.Technology, is a credible industry publication. Evidence is based on a controlled 119-person, 52-week observational feasibility trial at seven UK clinical sites.
Study Limitations
The study assessed feasibility only — it was not designed to detect treatment effects or predict individual cognitive outcomes. Generalizability beyond the UK trial population is unconfirmed. Readers should consult the full Frontiers in Digital Health publication for detailed methodology and statistical results.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: